Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.

Trends Mol Med 2018 02 4;24(2):187-196. Epub 2018 Jan 4.

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) and Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, M5S 1A8, Ontario, Canada.

Clinical medicine of the future is poised to use an individual's genomic data to predict disease risk and guide clinical care. The treatment of cigarette smoking and tobacco use disorder represents a prime area for genomics implementation. The genes CHRNA5 and CYP2A6 are strong genomic contributors that alter the risk of heaviness of smoking, tobacco use disorder, and smoking-related diseases in humans. These biomarkers have proven analytical and clinical validity, and evidence for their clinical utility continues to grow. We propose that these biomarkers harbor the potential of enabling the identification of elevated disease risk in smokers, personalizing smoking cessation treatments, and motivating behavioral changes. We must prepare for the integration of genomic applications into clinical care of patients who smoke.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2017.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812803PMC
February 2018
52 Reads

Publication Analysis

Top Keywords

clinical care
8
disease risk
8
smoking tobacco
8
tobacco disorder
8
clinical
5
validity evidence
4
clinical validity
4
analytical clinical
4
proven analytical
4
chrna5 cyp2a6
4
evidence clinical
4
genes chrna5
4
utility continues
4
clinical utility
4
biomarkers proven
4
cyp2a6 strong
4
heaviness smoking
4
alter risk
4
contributors alter
4
genomic contributors
4

Similar Publications